Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
18.9M
-
Shares change
-
+1.73M
-
Total reported value, excl. options
-
$227M
-
Value change
-
+$20.8M
-
Number of buys
-
43
-
Number of sells
-
-26
-
Price
-
$12.01
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2019
78 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q3 2019.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.9M shares
of 62.2M outstanding shares and own 30.38% of the company stock.
Largest 10 shareholders include FMR LLC (3.94M shares), FARALLON CAPITAL MANAGEMENT LLC (1.5M shares), BAKER BROS. ADVISORS LP (1.17M shares), BlackRock Inc. (1.08M shares), VHCP Management III, LLC (1.07M shares), VANGUARD GROUP INC (936K shares), MILLENNIUM MANAGEMENT LLC (838K shares), RTW INVESTMENTS, LP (762K shares), DIMENSIONAL FUND ADVISORS LP (731K shares), and BVF INC/IL (683K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.